Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

High Calcium, Vitamin D Intake Does Not Reduce Breast Cancer Risk – JNCI

This article was originally published in The Tan Sheet

Executive Summary

High calcium and vitamin D supplementation was not found to reduce the risk of invasive breast cancer in postmenopausal women in a Journal of the National Cancer Institute study

You may also be interested in...



“Breakthrough” Vitamin D Study Shows Reduced Cancer Risk

A study finding calcium plus vitamin D reduces the risk for developing cancer in postmenopausal women is a "breakthrough," according to the Council for Responsible Nutrition

Vitamin D Studies May Lend Support To Increased Upper Intake Level – Shao

Findings from two separate studies that suggest an increase in vitamin D intake can cut cancer risk by at least half may help "corral enough support" to look at increasing the upper intake level (UL)for vitamin D, according to Andrew Shao, Ph.D., VP scientific and regulatory affairs for the Council for Responsible Nutrition

MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In

The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102335

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel